First filing for Medivation's promising prostate cancer drug enzalutamide
This article was originally published in Scrip
Medivation has made the first regulatory filing for its androgen receptor signalling inhibitor enzalutamide (MDV3100), in the US for use in patients with progressive castration-resistant prostate cancer who have already received docetaxel-based chemotherapy.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.